Thromboplastin (Tissue Factor)

Subscribe to Selected New Research on Thromboplastin

2412 relevant articles (34 outcomes, 197 trials/studies) found for this Bio-Agent

Description: Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation.

Also Known As:

Tissue Factor; Blood Coagulation Factor III; Coagulin; Glomerular Procoagulant Activity; Prothrombinase; Tissue Factor Procoagulant; Urothromboplastin; Activity, Glomerular Procoagulant; Factor III, Coagulation; Procoagulant Activity, Glomerular; Procoagulant, Tissue Factor; Thromboplastin, Tissue; Antigens, CD142; CD142 Antigens; Coagulation Factor III; Factor III; Tissue Thromboplastin; Blood-coagulation factor III

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins

Proteins: 58433

Blood Proteins: 3862

Blood Coagulation Factors: 1580

Thromboplastin: 2412

endothelial cell procoagulant activity: 9

Innovin: 2

Thrombofax: 2

human thromboplastin apoprotein

Biological Factors: 931

Blood Coagulation Factors: 1580

Thromboplastin: 2412

endothelial cell procoagulant activity: 9

Innovin: 2

Thrombofax: 2

human thromboplastin apoprotein

Experts

1.	Mackman, Nigel: 24 articles (10/2008 - 01/2003)
2.	Ruf, Wolfram: 11 articles (10/2008 - 01/2003)
3.	Kisiel, Walter: 11 articles (05/2008 - 01/2002)
4.	Zhu, Jing: 7 articles (10/2007 - 07/2002)
5.	Taubman, Mark B: 6 articles (04/2008 - 09/2004)
6.	Pawlinski, Rafal: 6 articles (03/2008 - 05/2003)
7.	Fang, Jun: 6 articles (02/2008 - 12/2003)
8.	Wan, Yuan-lian: 6 articles (10/2007 - 02/2004)
9.	Pedersen, Brian: 6 articles (03/2006 - 05/2003)
10.	Rak, Janusz: 5 articles (09/2008 - 02/2004)

Related Diseases

1.	Disseminated Intravascular Coagulation 04/01/2008 - "Additionally, one should exercise caution if there is evidence of activated coagulation, such as that seen with excessive tissue factor release or disseminated intravascular coagulation. " 01/01/2002 - "CONCLUSION: Because pathophysiology differed remarkably between the tissue factor- and lipopolysaccharide-induced disseminated intravascular coagulation models in rats, we recommend that they be assessed carefully as distinct entities to determine implications of their experimental and clinical use." 01/01/2002 - "OBJECTIVE: Tissue factor and lipopolysaccharide frequently have been used to induce disseminated intravascular coagulation in experimental animal models. " 01/01/2002 - "Marked difference in pathophysiology between tissue factor- and lipopolysaccharide-induced disseminated intravascular coagulation models in rats." 12/01/2001 - "The tissue factor pathway in disseminated intravascular coagulation." Order ALL the reference details at left...
2.	Thrombosis (Thrombus) 03/01/1996 - "The aim of this study was to compare recombinant thromboplastin (rTF, ISI = 0.82) with rabbit thromboplastin (RT, ISI = 1.46) in order to evaluate which performed better in our thrombosis centre. " 01/01/1987 - "(1) Study on the role of tissue thromboplastin in the formation of thrombosis]" 11/01/2009 - "AIMS: Circulating tissue factor (TF) has been linked to thrombus propagation. " 10/15/2009 - "Consistent with a role for cytokine-driven thrombosis in fetal loss, expression of procoagulant tissue factor was significantly increased in the placentae of infected C57BL/6 mice but was reduced in mice treated with anti-TNF Ab. " 10/01/2009 - "They are the main carriers of circulating tissue factor, the principal initiator of intravascular thrombosis, and are implicated in a variety of thrombotic and inflammatory disorders. " Order ALL the reference details at left...
3.	Neoplasms (Cancer) 11/15/2009 - "In cancer patients without VTE, a retrospective analysis revealed a 1-year cumulative incidence of VTE of 34.8% in patients with tissue factor-bearing microparticles versus 0% in those without detectable tissue factor-bearing microparticles (Gray test P = 0.002).The median number of tissue factor-bearing microparticles in the cancer VTE cohort (7.1 x 10(4) microparticles/microL) was significantly greater than both the idiopathic VTE and cancer-no VTE groups (P = 0.002 and P = 0.03, respectively). " 10/01/2009 - "More studies are needed to clarify the mechanisms by which tissue factor affects cancer progression and outcome, and its potential role as a therapeutic target." 10/01/2009 - "Recent studies suggest that tissue factor, a primary initiator of the extrinsic coagulation pathway, is expressed in various solid tumors in association with increased angiogenesis. " 04/01/2008 - "OBJECTIVE: To study the effects of adenovirus-mediated tissue factor pathway inhibitor-2 gene on the invasion of laryngeal squamous cancer. " 03/01/2008 - "In recent years, studies increasingly suggested an association between the prothrombotic state in cancer patients and circulating tissue factor-exposing microparticles. " Order ALL the reference details at left...
4.	Hemorrhage 01/01/2009 - "This study was undertaken to evaluate prospectively how tissue factor (TF) activated TEG correlated to clinical signs of bleeding in dogs, compared to a routine coagulation profile. " 04/01/2008 - "A patient with spontaneous hemorrhage from multiple body sites was found to have markedly prolonged international normalized ratio (INR) and activated partial thromboplastin times (aPTT) with incomplete correction of aPTT on mixing studies using normal plasma. " 01/01/2005 - "This study investigates the predictive value of commonly used coagulation tests (thromboplastin time, partial thromboplastin time and thrombocyte count) compared with a standardized bleeding history. " 07/01/1981 - "The Australasian Reference Thromboplastin: I. A study in bleeding patients." 01/15/2009 - "TF-deficient mice were generated with the expected frequency, showed no evidence of bleeding or increased mortality, and had similar activated partial thromboplastin and tail vein bleeding times. " Order ALL the reference details at left...
5.	Myocardial Infarction 02/01/2009 - "This study was aimed to investigate the change of tissue factor pathway (TFP) ratio during the attack of acute myocardial infarction (AMI) and its clinical significance. " 06/01/2009 - "Increased levels of procoagulant tissue factor-bearing microparticles within the occluded coronary artery of patients with ST-segment elevation myocardial infarction: role of endothelial damage and leukocyte activation." 02/01/2009 - "[Change of tissue factor pathway ratio during attack in patients with acute myocardial infarction and its clinical significance]" 08/01/2008 - "Here, we compared the in vivo expression of LOX-1, with tissue factor (TF) expression and cell apoptosis, in atherosclerotic lesions of myocardial infarction-prone Watanabe heritable hyperlipidemic (WHHLMI) rabbits. " 01/01/2005 - "In acute myocardial infarction (AMI), increased Tissue Factor (TF) expression on circulating monocytes and microparticles (MP) may contribute to thrombotic events. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Factor Xa (Coagulation Factor Xa)
2.	Thrombin
3.	Heparin (Liquaemin)
4.	Prothrombin (Factor II)
5.	Anticoagulants
6.	Dacarbazine (DIC)
7.	Thrombomodulin
8.	Fibrinogen (Factor I)
9.	Plasminogen Activators (Plasminogen Activator)
10.	Antithrombin III

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Drug Therapy (Chemotherapy)
3.	Stents
4.	Peritoneal Dialysis
5.	Balloon Angioplasty (Angioplasty, Transluminal)

Best Treatments:
Research Summary Report
on Disseminated Intravascular Coagulation

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 101 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>